The peptide distributes systemically and migrates to injury sites
How often do you need vitamin B12 injections
It upregulates the expression of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and their respective receptors at sites of injury, directly promoting angiogenesis and epithelial repair
This triple agonist design, developed by Eli Lilly under the research code LY3437943, represents a fundamentally different approach from semaglutide (which targets only GLP-1) or tirzepatide (which targets GLP-1 and GIP)
Current studies focus on how modulating this process could relate to metabolic balance, immune activity,
It has been studied in dermatitis, eczema, and psoriasisrelated research, where its barriersupportive effects add to its antiinflammatory activity